Dashboard
Manage Tickers

FATE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-upgrades-fate-therapeutics-to-buy-maintains-price-target-to-5
HC Wainwright & Co. Upgrades Fate Therapeu...
10/31/2025 10:54:45

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the ...

wedbush-upgrades-fate-therapeutics-to-outperform-raises-price-target-to-7
Wedbush Upgrades Fate Therapeutics to Outp...
10/27/2025 12:40:03

Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price ...

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
10/27/2025 09:40:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

reported-sunday-fate-therapeutics-presents-ft819-phase-1-data-demonstrating-immune-remodeling-and-durable-responses-in-10-patients-with-systemic-lupus-erythematosus
Reported Sunday, Fate Therapeutics Present...
10/27/2025 06:37:45

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythema...

fate-therapeutics-appoints-kamal-adawi-as-cfo-effective-october-20
Fate Therapeutics Appoints Kamal Adawi As ...
10/14/2025 12:05:04

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

wells-fargo-maintains-equal-weight-on-fate-therapeutics-lowers-price-target-to-25
Wells Fargo Maintains Equal-Weight on Fate...
08/13/2025 12:52:11

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from...

fate-therapeutics-q2-eps-029-beats-034-estimate-sales-1907m-beat-1011m-estimate
Fate Therapeutics Q2 EPS $(0.29) Beats $(0...
08/12/2025 20:17:59

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0...

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
06/12/2025 12:27:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

fate-therapeutics-announces-new-and-updated-clinical-data-from-first-five-patients-dosed-with-ft819-for-treatment-of-moderate-to-severe-sle-at-eular-2025-congress
Fate Therapeutics Announces New And Update...
06/11/2025 13:02:32

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primar...

fate-therapeutics-reveals-phase-1-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-sle-at-eular-2025-congress
Fate Therapeutics Reveals Phase 1 Data Pre...
05/28/2025 21:56:24

barclays-maintains-overweight-on-fate-therapeutics-lowers-price-target-to-2
Barclays Maintains Overweight on Fate Ther...
05/14/2025 14:56:43

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and lowers the price target from $...

4-analysts-assess-fate-therapeutics-what-you-need-to-know
4 Analysts Assess Fate Therapeutics: What ...
05/14/2025 14:00:41

baird-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-4
Baird Maintains Neutral on Fate Therapeuti...
05/14/2025 13:14:28

Baird analyst Jack Allen maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $5 to $4.

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
05/14/2025 11:31:55

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

fate-therapeutics-q1-eps-032-beats-038-estimate-sales-163m-beat-114m-estimate
Fate Therapeutics Q1 EPS $(0.32) Beats $(0...
05/13/2025 20:12:11

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0...

fate-therapeutics-wins-regenerative-medicine-advanced-therapy-designation-from-fda-for-ft819-to-treat-moderate-to-severe-systemic-lupus-erythematosus
Fate Therapeutics Wins Regenerative Medici...
04/14/2025 12:05:22

–   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue w...

stifel-maintains-hold-on-fate-therapeutics-lowers-price-target-to-3
Stifel Maintains Hold on Fate Therapeutics...
03/06/2025 15:59:11

Stifel analyst Benjamin Burnett maintains Fate Therapeutics (NASDAQ:FATE) with a Hold and lowers the price target from $5 to...

wedbush-reiterates-neutral-on-fate-therapeutics-maintains-5-price-target
Wedbush Reiterates Neutral on Fate Therape...
03/06/2025 14:10:44

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $5 price target.

wells-fargo-maintains-equal-weight-on-fate-therapeutics-lowers-price-target-to-4
Wells Fargo Maintains Equal-Weight on Fate...
03/06/2025 14:00:01

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION